Adoptive cell therapies
to cure patients
Carla Biotherapeutics develops cell-based immunotherapies to treat a broad range of diseases with a first focus on hematological malignancies and solid tumors
CARLA Biotherapeutics, a Landmark BioVentures nexus company
Next-generation precision CAR-T immunotherapies
Carla Biotherapeutics is a preclinical stage company advancing lead programs targeting hematological malignancies and solid tumors. We are advancing a proprietary CAR-T platform plug-and-play technology to rapidly and efficiently develop precision medicines for severe and aggressive diseases.
Backed by over 100 years of collective deep scientific domain and drug development expertise, Carla is well-positioned for success while operating within a unique ecosystem combining clinical, translational and immune cell-based therapy.